1. Home
  2. TYRA vs VALN Comparison

TYRA vs VALN Comparison

Compare TYRA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • VALN
  • Stock Information
  • Founded
  • TYRA 2018
  • VALN 2012
  • Country
  • TYRA United States
  • VALN France
  • Employees
  • TYRA N/A
  • VALN N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • VALN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TYRA Health Care
  • VALN Health Care
  • Exchange
  • TYRA Nasdaq
  • VALN Nasdaq
  • Market Cap
  • TYRA 667.3M
  • VALN 777.9M
  • IPO Year
  • TYRA 2021
  • VALN 2021
  • Fundamental
  • Price
  • TYRA $12.11
  • VALN $8.95
  • Analyst Decision
  • TYRA Strong Buy
  • VALN Strong Buy
  • Analyst Count
  • TYRA 8
  • VALN 4
  • Target Price
  • TYRA $31.00
  • VALN $15.75
  • AVG Volume (30 Days)
  • TYRA 243.4K
  • VALN 129.1K
  • Earning Date
  • TYRA 11-06-2025
  • VALN 11-06-2025
  • Dividend Yield
  • TYRA N/A
  • VALN N/A
  • EPS Growth
  • TYRA N/A
  • VALN N/A
  • EPS
  • TYRA N/A
  • VALN N/A
  • Revenue
  • TYRA N/A
  • VALN $230,566,060.00
  • Revenue This Year
  • TYRA N/A
  • VALN $15.55
  • Revenue Next Year
  • TYRA N/A
  • VALN $23.93
  • P/E Ratio
  • TYRA N/A
  • VALN N/A
  • Revenue Growth
  • TYRA N/A
  • VALN 25.47
  • 52 Week Low
  • TYRA $6.42
  • VALN $3.62
  • 52 Week High
  • TYRA $29.60
  • VALN $12.25
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 54.50
  • VALN 49.63
  • Support Level
  • TYRA $11.70
  • VALN $8.76
  • Resistance Level
  • TYRA $12.91
  • VALN $9.46
  • Average True Range (ATR)
  • TYRA 0.67
  • VALN 0.33
  • MACD
  • TYRA -0.04
  • VALN -0.13
  • Stochastic Oscillator
  • TYRA 30.38
  • VALN 65.41

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: